When data becomes available in the coming weeks on different applications, we will begin to spend some time reprioritizing our MANF pipeline to ensure that we are maximizing shareholder value
Fine. First of all nary a single AMBS investor/trader has not read and absorbed that info...with consequent pps result for today.
Secondly, let's say the 'repriortization' rearranges MANF for eye, ear, nose, throat and CNS indications. So what? They're still years away from clinical results and commercialization For any MANF indication.
LymPro results, grants....for anything AMBS is doing....and JV announcement. That's it as far as pps movers for AMBS.
Go take a ride through the 'Magic Mountain' and see what else you can come up with. We've already heard about 'Tommorowland'!